FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its Phase 1 study assessing Lucid-21-302, or Lucid-MS, has completed dosing.
Conducted by the company’s wholly-owned subsidiary Lucid Psycheceuticals, the randomized, double-blind, placebo-controlled and both single- and multiple-ascending dose trial aims to assess Lucid-MS, a small molecule inhibitor of hypercitrullination, as a …